Not Approved (US) Longevity & Mitochondrial

Ventfort

also known as: Vascular peptide bioregulator, Vessel-wall peptide preparation

The Khavinson vascular bioregulator, marketed in Russia for endothelial aging and microcirculation support. Associated with the synthetic KEDG tetrapeptide in some Khavinson-group publications. Russian-language evidence base only; not FDA/EMA approved.

A short peptide bioregulator preparation derived from bovine vascular tissue in the Khavinson cytomedine series, marketed in Russia for age-related vascular decline, endothelial dysfunction, and microcirculatory support. The characterized synthetic active tetrapeptide associated with Ventfort in some Khavinson publications is Lys-Glu-Asp-Gly (KEDG). Evidence base and regulatory status are identical to the rest of the Khavinson short-peptide series: Russian nutraceutical status only, no independent Western clinical validation.

Mechanism of action

Proposed to support endothelial aging and vascular homeostasis via the Khavinson-framework tissue-specific gene-expression modulation hypothesis. Not independently validated in Western literature.

Primary uses

Vascular / endothelial aging support (Russian nutraceutical positioning)
Microcirculatory support (anecdotal)

Typical dosing

1–2 capsules 1–2 times daily in 20–30 day courses (oral)

Russian nutraceutical dosing. No controlled efficacy evidence.

Regulatory status

Not FDA- or EMA-approved. Sold in Russia and CIS states as a nutraceutical; not a registered medicine in any Western jurisdiction.

References

[review] Khavinson VK, et al. "Short peptides and tissue-specific gene expression: the Khavinson bioregulator framework." Bull Exp Biol Med, 2011;151:1-8.
[review] Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology, 2010;11:139-149.

Related peptides

Vesugen

The synthetic KED tripeptide in the Khavinson short-peptide series, studied preclinically for vascular-aging and antiatherogenic effects. Not a registered medicine; research-only in the West, nutraceutical status in Russia. Preclinical evidence only.

Cardiogen

A Khavinson-group tetrapeptide from heart-tissue extract — proposed to support cardiomyocyte function and cardiac tissue aging; evidence base is Russian-language and largely pre-clinical.

Epithalon

A synthetic pineal tetrapeptide from the Khavinson group (St. Petersburg) — the only peptide with published data claiming telomerase activation and telomere elongation in human cell models.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.